Hyperfine (HYPR) Revenue & Revenue Breakdown
Hyperfine Revenue Highlights
Latest Revenue (Y)
$11.03M
Latest Revenue (Q)
$3.63M
Main Geography (Y)
Non-US
Hyperfine Revenue by Period
Hyperfine Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $11.03M | 61.90% |
2022-12-31 | $6.81M | 355.48% |
2021-12-31 | $1.50M | 408.84% |
2020-12-31 | $294.00K | 100.00% |
2019-12-31 | - | - |
Hyperfine Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $3.63M | 10.20% |
2024-03-31 | $3.29M | 22.67% |
2023-12-31 | $2.69M | 15.28% |
2023-09-30 | $2.33M | -31.09% |
2023-06-30 | $3.38M | 28.31% |
2023-03-31 | $2.63M | 85.04% |
2022-12-31 | $1.42M | -39.35% |
2022-09-30 | $2.35M | 53.16% |
2022-06-30 | $1.53M | 1.59% |
2022-03-31 | $1.51M | 246.10% |
2021-12-31 | $436.00K | 17.52% |
2021-09-30 | $371.00K | 3.63% |
2021-06-30 | $358.00K | 8.16% |
2021-03-31 | $331.00K | 59.90% |
2020-12-31 | $207.00K | 459.46% |
2020-09-30 | $37.00K | 48.00% |
2020-06-30 | $25.00K | - |
2020-03-31 | $25.00K | - |
Hyperfine Revenue Breakdown
Hyperfine Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Mar 24 | Sep 23 | Jun 23 | Mar 23 |
---|---|---|---|---|
Service | $591.00K | $602.00K | $114.00K | - |
Product | $2.70M | $1.73M | $2.81M | - |
Hyperfine Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
Non-US | $4.36M | $2.54M | - |
AUSTRALIA | - | - | $78.00K |
Quarterly Revenue by Country
Country | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|
Non-US Countries | $2.43M | $65.00K | $2.90M | $1.03M | $784.00K | $561.00K | - | - |
Service | - | - | - | $114.00K | - | - | - | - |
Non-US | - | - | - | - | $591.00K | - | - | - |
Canada and Pakistan | - | - | - | - | - | - | - | $509.00K |
Hyperfine Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
PAVM | PAVmed | $2.45B | $979.00M |
ITGR | Integer | $1.60B | $753.01M |
LIVN | LivaNova | $1.15B | $318.60M |
INGN | Inogen | $315.66M | $88.77M |
ANIK | Anika Therapeutics | $166.66M | $41.92M |
KIDS | OrthoPediatrics | $148.73M | $52.80M |
SRDX | Surmodics | $132.58M | $30.34M |
LUNG | Pulmonx | $68.67M | $20.78M |
IRMD | IRadimed | $65.56M | $17.93M |
NPCE | NeuroPace | $65.42M | $18.12M |
APYX | Apyx Medical | $52.35M | $12.15M |
OSA | ProSomnus | $27.65M | $7.46M |
HYPR | Hyperfine | $11.03M | $3.63M |
OFIX | Orthofix Medical | $100.00K | $198.62M |
HYPR Revenue FAQ
What is Hyperfine’s yearly revenue?
Hyperfine's yearly revenue for 2023 was $11.03M, representing an increase of 61.90% compared to 2022. The company's yearly revenue for 2022 was $6.81M, representing an increase of 355.48% compared to 2021. HYPR's yearly revenue for 2021 was $1.5M, representing an increase of 408.84% compared to 2020.
What is Hyperfine’s quarterly revenue?
Hyperfine's quarterly revenue for Q2 2024 was $3.63M, a 10.20% increase from the previous quarter (Q1 2024), and a 7.39% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $3.3M, a 22.67% increase from the previous quarter (Q4 2023), and a 25.05% increase year-over-year (Q1 2023). HYPR's quarterly revenue for Q4 2023 was $2.69M, a 15.28% increase from the previous quarter (Q3 2023), and a 88.62% increase year-over-year (Q4 2022).
What is Hyperfine’s revenue growth rate?
Hyperfine's revenue growth rate for the last 3 years (2021-2023) was 637.43%, and for the last 5 years (2019-2023) was 0%.